Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s chief executive Prof Lindy Durrant talks to Proactive after enrolling and treating the first patient with its Modi-1 cancer vaccine.
This is all part of their trial in patients with triple negative breast cancer as well as ovarian, head and neck and renal cancer.
With more than 100 patients recruited, the initial part of the trial aims to assess the safety and immunogenicity of two citrullinated vimentin peptides and, if there are no significant side effects, a citrullinated enolase peptide will be added.